A Phase 2 Adult Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol

Trial Profile

A Phase 2 Adult Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Gaboxadol (Primary)
  • Indications Angelman syndrome
  • Focus Therapeutic Use
  • Acronyms STARS
  • Sponsors Ovid Therapeutics
  • Most Recent Events

    • 13 Jun 2017 According to an Ovid Therapeutics media release, the company expects topline data from the trial to be available in 2018.
    • 09 Feb 2017 According to an Ovid Therapeutics media release, the first patient has been randomized in thsi trial.
    • 03 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top